Lilly Forteo Follow-Up Rat Osteosarcoma Study To Finish By End Of 2002

Lilly's follow-up Forteo (teriparatide) osteosarcoma study is expected to be completed by the end of 2002, FDA told the Endocrinologic and Metabolic Drugs Advisory Committee July 27.